Pharmaceutical company

Boehringer Ingelheim
clinical trial
pipeline

Registry checked

Published

Obrixtamig is linked to 12 distinct active studies, with 7 Phase 1, 3 Phase 2, 2 Phase 3. Nerandomilast is linked to 7 distinct active studies, with 7 Phase 3. Survodutide is linked to 8 distinct active studies, with 2 Phase 1, 6 Phase 3.

Phase 3 study NCT06151574 in Lung Cancer, Non-squamous, Non-small Cell lists estimated primary completion on 10 December 2026. These are registry estimates of primary completion, not confirmed results announcements or overall study completion.

Active trial mix

Lead-sponsor scope

96active trials
as lead sponsor
  • Phase 141
  • Phase 220
  • Phase 326
  • Phase 40
  • Phase not recorded9

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

02 Oct 2026 – 31 Oct 2026 · UTC

Recorded changes

3924 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

03Primary completion

Primary completion moved later by 426 days

2026-12-30 (estimated)2028-02-29 (estimated)
30 Dec 202629 Feb 2028

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

NCT04886804 · ClinicalTrials.gov
Recorded by ComplyRx
29 Oct 2026
Registry last updated
28 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-021100021
2026-10-031011032
2026-10-040000000
2026-10-050000000
2026-10-060000111
2026-10-071110031
2026-10-080000000
2026-10-090000000
2026-10-100000000
2026-10-110000000
2026-10-120000000
2026-10-131000232
2026-10-143330096
2026-10-152100144
2026-10-160100121
2026-10-170000000
2026-10-180000000
2026-10-191000011
2026-10-200000000
2026-10-210000000
2026-10-220000000
2026-10-230000000
2026-10-240000000
2026-10-250000000
2026-10-260000000
2026-10-270000000
2026-10-280200022
2026-10-293120064
2026-10-300000221
2026-10-310000111
Type totals13107183924 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Obrixtamig

Canonical investigational asset

12
Active trials
6
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 17
  • Phase 23
  • Phase 32
  • Phase 40
  • Phase not recorded0
Studied condition
Advanced Small Cell Lung Cancer · Extensive-stage Small Cell Lung Cancer (ES-SCLC) · Extensive-stage Small Cell Lung Carcinoma
Next primary completion
Not reported
Open drug

Survodutide

Canonical investigational asset

8
Active trials
3
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 12
  • Phase 20
  • Phase 36
  • Phase 40
  • Phase not recorded0
Studied condition
Liver Fibrosis · Metabolic Dysfunction Associated Steatohepatitis · Metabolic Dysfunction Associated Steatohepatitis (MASH)
Next primary completion
Not reported
Open drug

Nerandomilast

jascayd

7
Active trials
4
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 37
  • Phase 40
  • Phase not recorded0
Studied condition
Familial Pulmonary Fibrosis · Fibrosing Interstitial Lung Disease · Idiopathic Inflammatory Myopathies
Next primary completion
15 April 2027 · estimated
Open drug

Verducatib

Canonical investigational asset

6
Active trials
4
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 13
  • Phase 21
  • Phase 32
  • Phase 40
  • Phase not recorded0
Studied condition
Bronchiectasis · Chronic Obstructive Pulmonary Disease · Healthy
Next primary completion
31 March 2027 · estimated
Open drug

zongertinib

hernexeos

6
Active trials
5
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 11
  • Phase 23
  • Phase 32
  • Phase 40
  • Phase not recorded0
Studied condition
Colorectal Cancer · Esophageal Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma
Next primary completion
10 December 2026 · estimated
Open drug

Vicadrostat

Canonical investigational asset

5
Active trials
4
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 11
  • Phase 20
  • Phase 34
  • Phase 40
  • Phase not recorded0
Studied condition
Cardiovascular Diseases · Diabetes Mellitus, Type 2 · Healthy
Next primary completion
31 December 2026 · estimated
Open drug

84 of 96 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 84 of 96 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

Boehringer Ingelheim trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
zongertinib

NCT06151574

Phase 3 · Active, not recruiting

Trial source and qualifications

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 6 inspected observations were not displayed.

7 candidate observations · 1 shown · 0 recorded after primary completion · 6 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

6 inspected observations omitted. At most three verified observations are shown, not full history.

  • pc date moved · Recorded 2026-09-23 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

Start: 09 Feb 2024 · actual
Primary completion: 10 Dec 2026 · estimated
Study completion: 28 Jan 2028 · estimated

2021202220232024202520262027202820292030
A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
BI 1584862

NCT06769048

Phase 2 · Active, not recruiting

Trial source and qualifications

A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 3 inspected observations were not displayed.

4 candidate observations · 1 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

3 inspected observations omitted. At most three verified observations are shown, not full history.

  • pc date moved · Recorded 2026-07-29 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

Start: 31 Jan 2025 · actual
Primary completion: 22 Dec 2026 · estimated
Study completion: 05 Jan 2027 · estimated

2021202220232024202520262027202820292030
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
Vicadrostat

NCT06531824

Phase 3 · Active, not recruiting

Trial source and qualifications

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

3 candidate observations · 3 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

Up to three verified eligible observations in the bounded history window.

  • pc date moved · Recorded 2026-09-23 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
  • status flip · Recorded 2026-09-23 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
  • enrollment change · Recorded 2026-10-14 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

Start: 30 Aug 2024 · actual
Primary completion: 31 Dec 2026 · estimated
Study completion: 31 Dec 2026 · estimated

2021202220232024202520262027202820292030
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
BI 764524

NCT06321302

Phase 2 · Recruiting

Trial source and qualifications

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 4 inspected observations were not displayed.

5 candidate observations · 1 shown · 0 recorded after primary completion · 4 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

4 inspected observations omitted. At most three verified observations are shown, not full history.

  • status flip · Recorded 2026-10-15 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

Start: 15 May 2024 · actual
Primary completion: 05 Mar 2027 · estimated
Study completion: 20 Aug 2027 · estimated

2021202220232024202520262027202820292030
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
BI 765423

NCT07036523

Phase 2 · Active, not recruiting

Trial source and qualifications

A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

4 candidate observations · 2 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

2 inspected observations omitted. At most three verified observations are shown, not full history.

  • status flip · Recorded 2026-09-26 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
  • enrollment change · Recorded 2026-09-26 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

Start: 13 Nov 2025 · actual
Primary completion: 11 Mar 2027 · estimated
Study completion: 22 Jun 2027 · estimated

2021202220232024202520262027202820292030
A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated
Low dose BI 3812465

NCT07553429

Phase 2 · Recruiting

Trial source and qualifications

A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

1 inspected observations omitted. At most three verified observations are shown, not full history.

    Start: 14 May 2026 · actual
    Primary completion: 23 Mar 2027 · estimated
    Study completion: 06 Jul 2027 · estimated

    2021202220232024202520262027202820292030

    Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

    6 selected of 42 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 0 actual primary completions, 0 untyped primary completions, 1 past estimates, 3 outside the horizon, 0 contradictory dates.

    04 / Therapeutic focus

    Where the activity is

    33

    active trials in Oncology

    Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

    Active trials by primary therapeutic area

    • Oncology33 trials
    • Metabolic/Endocrine/Nutrition15 trials
    • Respiratory10 trials
    • Renal & Urology5 trials
    • Cardiovascular4 trials
    • Ophthalmology4 trials
    • Gastroenterology & Hepatology3 trials
    • Immunology & Inflammation3 trials
    • Neurology1 trials
    • Unmapped8 trials
    • Healthy volunteers10 trials

    Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

    06 / Related companies

    All companies

    No supported overlap was identified in the selected programme context. Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

    Sources, scope and methodology

    ClinicalTrials.gov lead-sponsor scope

    Canonical current-owner attribution covers 2,299 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: Boehringer Ingelheim. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion.

    ClinicalTrials.gov

    Attribution coverage

    2,299 distinct registry candidates produced 2,299 accepted studies. 0 mapped to other owners, 0 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 0 unverified, 0 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

    Indexed enrichment

    1,946 scoped records have indexed enrichment and 353 do not. Missing enrichment does not remove a trial from cohort counts.

    Scope observation

    The successful attribution check completed at 2026-11-01T04:09:51.973Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot 29ec96fff597560a38b9453f7662d45af53a66b57ba0ee461417224ba75ea504.

    Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

    Dated canonical-attribution snapshot: 2,299 mapped lead-sponsored clinical studies across all statuses. 1,946 have indexed enrichment, 353 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

    Keep following
    what matters.

    Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

    Build your watch

    Choose what to track in the watch builder.